Related Experiment Video

Updated: Aug 20, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours

M Ng1, D Cunningham

  • 1The Royal Marsden Hospital, Sutton, UK.

International Journal of Clinical Practice
|December 14, 2004
PubMed

Insights

Cetuximab, a targeted therapy, shows promise in treating solid tumors by inhibiting epidermal growth factor receptor (EGFR). This antibody can enhance chemotherapy and radiotherapy efficacy with manageable toxicity in cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Epidermal growth factor receptor (EGFR) is a key target in cancer therapy due to its over-expression in solid tumors.
  • EGFR deregulation correlates with chemoresistance, radioresistance, and poor patient prognosis.
  • Targeting EGFR offers a rational approach to improve cancer treatment outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of cetuximab, a monoclonal antibody against EGFR.
  • To explore the potential of combining cetuximab with chemotherapy and radiotherapy.
  • To assess the impact of cetuximab on cancer treatment efficacy and toxicity.

Main Methods:

  • Cetuximab, a chimeric monoclonal antibody, was developed to target EGFR.
  • Studies investigated cetuximab's activity as a standalone therapy and in combination regimens.
  • Clinical trials assessed efficacy across various tumor types and evaluated toxicity profiles.

Main Results:

  • Cetuximab demonstrated significant activity in multiple tumor types.
  • Combination therapy with cetuximab, chemotherapy, and radiotherapy showed enhanced efficacy.
  • The addition of cetuximab did not substantially increase treatment-related toxicity.

Conclusions:

  • Cetuximab is an effective therapeutic agent targeting EGFR in solid tumors.
  • Combining cetuximab with standard chemotherapy and radiotherapy represents a promising strategy.
  • This approach offers improved cancer treatment outcomes with a manageable safety profile.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...